Neurocrine Cash And Short Term Investments vs Other Current Assets Analysis

NBIX Stock

USD 135.41 1.25 0.91%

Neurocrine Biosciences financial indicator trend analysis is infinitely more than just investigating Neurocrine Biosciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neurocrine Biosciences is a good investment. Please check the relationship between Neurocrine Biosciences Cash And Short Term Investments and its Other Current Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Cash And Short Term Investments vs Other Current Assets

Cash And Short Term Investments vs Other Current Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neurocrine Biosciences Cash And Short Term Investments account and Other Current Assets. At this time, the significance of the direction appears to have strong relationship.

The correlation between Neurocrine Biosciences' Cash And Short Term Investments and Other Current Assets is 0.63. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Other Current Assets in the same time period over historical financial statements of Neurocrine Biosciences, assuming nothing else is changed. The correlation between historical values of Neurocrine Biosciences' Cash And Short Term Investments and Other Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Neurocrine Biosciences are associated (or correlated) with its Other Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Assets has no effect on the direction of Cash And Short Term Investments i.e., Neurocrine Biosciences' Cash And Short Term Investments and Other Current Assets go up and down completely randomly.

Correlation Coefficient

0.63

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Neurocrine Biosciences balance sheet. This account contains Neurocrine Biosciences investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Neurocrine Biosciences fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Most indicators from Neurocrine Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neurocrine Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.At this time, Neurocrine Biosciences' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 63.8 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 22.9 M in 2024.

Neurocrine Biosciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Other Liab	Other Assets
Total Assets		0.37	0.52	0.9	0.99	0.97	0.39	0.47	0.98	0.46	0.99	0.86	0.95	0.97	0.45	0.68	0.55	0.9	0.96	0.94	0.99	0.52	0.87	0.93	0.21	0.79
Short Long Term Debt Total	0.37		0.12	0.36	0.32	0.36	0.2	-0.45	0.33	0.26	0.36	0.23	0.46	0.28	0.7	0.42	-0.02	0.64	0.45	0.35	0.38	0.37	0.29	0.4	0.33	0.26
Other Current Liab	0.52	0.12		0.55	0.51	0.37	0.2	0.15	0.5	0.53	0.46	0.14	0.59	0.49	0.49	0.26	0.96	0.52	0.51	0.28	0.57	0.44	0.68	0.54	-0.17	0.6
Total Current Liabilities	0.9	0.36	0.55		0.88	0.91	0.58	0.42	0.95	0.23	0.88	0.81	0.86	0.92	0.37	0.41	0.53	0.8	0.89	0.89	0.91	0.81	0.74	0.89	0.23	0.6
Total Stockholder Equity	0.99	0.32	0.51	0.88		0.96	0.32	0.54	0.98	0.43	0.98	0.88	0.92	0.99	0.41	0.62	0.54	0.88	0.91	0.94	0.97	0.46	0.87	0.9	0.21	0.8
Property Plant And Equipment Net	0.97	0.36	0.37	0.91	0.96		0.37	0.57	0.98	0.34	0.98	0.91	0.86	0.96	0.29	0.59	0.37	0.81	0.91	1.0	0.92	0.53	0.81	0.86	0.19	0.74
Net Debt	0.39	0.2	0.2	0.58	0.32	0.37		-0.03	0.43	-0.37	0.36	0.34	0.41	0.38	0.21	0.21	0.22	0.4	0.5	0.36	0.41	0.74	0.13	0.41	0.38	-0.18
Retained Earnings	0.47	-0.45	0.15	0.42	0.54	0.57	-0.03		0.55	0.01	0.53	0.61	0.23	0.58	-0.45	0.02	0.22	0.06	0.3	0.58	0.39	0.02	0.48	0.27	-0.11	0.44
Accounts Payable	0.98	0.33	0.5	0.95	0.98	0.98	0.43	0.55		0.34	0.97	0.9	0.9	0.99	0.35	0.55	0.52	0.84	0.93	0.97	0.96	0.6	0.84	0.9	0.22	0.74
Cash	0.46	0.26	0.53	0.23	0.43	0.34	-0.37	0.01	0.34		0.42	0.1	0.55	0.33	0.52	0.66	0.54	0.5	0.49	0.28	0.49	-0.02	0.63	0.49	-0.27	0.84
Non Current Assets Total	0.99	0.36	0.46	0.88	0.98	0.98	0.36	0.53	0.97	0.42		0.86	0.9	0.96	0.37	0.67	0.48	0.86	0.94	0.97	0.95	0.47	0.86	0.86	0.16	0.78
Non Currrent Assets Other	0.86	0.23	0.14	0.81	0.88	0.91	0.34	0.61	0.9	0.1	0.86		0.74	0.92	0.15	0.39	0.19	0.69	0.75	0.93	0.82	0.41	0.63	0.76	0.43	0.55
Cash And Short Term Investments	0.95	0.46	0.59	0.86	0.92	0.86	0.41	0.23	0.9	0.55	0.9	0.74		0.9	0.63	0.73	0.63	0.96	0.95	0.83	0.98	0.57	0.83	0.98	0.26	0.76
Net Receivables	0.97	0.28	0.49	0.92	0.99	0.96	0.38	0.58	0.99	0.33	0.96	0.92	0.9		0.35	0.52	0.52	0.84	0.89	0.95	0.96	0.53	0.83	0.9	0.27	0.74
Common Stock Shares Outstanding	0.45	0.7	0.49	0.37	0.41	0.29	0.21	-0.45	0.35	0.52	0.37	0.15	0.63	0.35		0.51	0.47	0.74	0.5	0.25	0.52	0.33	0.39	0.57	0.31	0.39
Non Current Liabilities Total	0.68	0.42	0.26	0.41	0.62	0.59	0.21	0.02	0.55	0.66	0.67	0.39	0.73	0.52	0.51		0.34	0.72	0.78	0.56	0.68	0.13	0.64	0.63	0.07	0.63
Other Current Assets	0.55	-0.02	0.96	0.53	0.54	0.37	0.22	0.22	0.52	0.54	0.48	0.19	0.63	0.52	0.47	0.34		0.52	0.53	0.29	0.61	0.36	0.7	0.58	-0.07	0.6
Other Stockholder Equity	0.9	0.64	0.52	0.8	0.88	0.81	0.4	0.06	0.84	0.5	0.86	0.69	0.96	0.84	0.74	0.72	0.52		0.91	0.78	0.93	0.53	0.75	0.91	0.31	0.69
Total Liab	0.96	0.45	0.51	0.89	0.91	0.91	0.5	0.3	0.93	0.49	0.94	0.75	0.95	0.89	0.5	0.78	0.53	0.91		0.89	0.96	0.62	0.83	0.92	0.2	0.73
Property Plant And Equipment Gross	0.94	0.35	0.28	0.89	0.94	1.0	0.36	0.58	0.97	0.28	0.97	0.93	0.83	0.95	0.25	0.56	0.29	0.78	0.89		0.9	0.51	0.77	0.83	0.22	0.7
Total Current Assets	0.99	0.38	0.57	0.91	0.97	0.92	0.41	0.39	0.96	0.49	0.95	0.82	0.98	0.96	0.52	0.68	0.61	0.93	0.96	0.9		0.56	0.86	0.97	0.26	0.78
Short Term Debt	0.52	0.37	0.44	0.81	0.46	0.53	0.74	0.02	0.6	-0.02	0.47	0.41	0.57	0.53	0.33	0.13	0.36	0.53	0.62	0.51	0.56		0.33	0.64	0.16	0.19
Intangible Assets	0.87	0.29	0.68	0.74	0.87	0.81	0.13	0.48	0.84	0.63	0.86	0.63	0.83	0.83	0.39	0.64	0.7	0.75	0.83	0.77	0.86	0.33		0.79	0.09	0.89
Short Term Investments	0.93	0.4	0.54	0.89	0.9	0.86	0.41	0.27	0.9	0.49	0.86	0.76	0.98	0.9	0.57	0.63	0.58	0.91	0.92	0.83	0.97	0.64	0.79		0.27	0.75
Other Liab	0.21	0.33	-0.17	0.23	0.21	0.19	0.38	-0.11	0.22	-0.27	0.16	0.43	0.26	0.27	0.31	0.07	-0.07	0.31	0.2	0.22	0.26	0.16	0.09	0.27		-0.14
Other Assets	0.79	0.26	0.6	0.6	0.8	0.74	-0.18	0.44	0.74	0.84	0.78	0.55	0.76	0.74	0.39	0.63	0.6	0.69	0.73	0.7	0.78	0.19	0.89	0.75	-0.14

Click cells to compare fundamentals

Neurocrine Biosciences Account Relationship Matchups

Neurocrine Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.3B	1.7B	2.1B	2.4B	3.3B	3.4B
Short Long Term Debt Total	495.5M	412.3M	440.4M	262.9M	428.4M	449.8M
Other Current Liab	156.5M	147.1M	194.3M	292M	35.9M	42.1M
Total Current Liabilities	565.3M	186.5M	245.8M	537.7M	654.8M	687.5M
Total Stockholder Equity	636.9M	1.1B	1.4B	1.7B	2.2B	2.3B
Property Plant And Equipment Net	116.2M	127.4M	155.8M	145.6M	347.3M	364.7M
Net Debt	383.2M	(388.7M)	99.6M	169.4M	177.3M	186.2M
Retained Earnings	(1.1B)	(725.4M)	(635.8M)	(406.8M)	(157.1M)	(165.0M)
Accounts Payable	46.2M	39.4M	51.5M	76.3M	108.9M	114.3M
Cash	112.3M	801M	340.8M	262.9M	251.1M	131.9M
Non Current Assets Total	475M	718.5M	1.1B	915.2M	1.6B	1.7B
Non Currrent Assets Other	3.2M	6.4M	4.4M	25M	49.6M	52.1M
Cash And Short Term Investments	670.5M	801M	711.3M	989.3M	1.0B	1.1B
Net Receivables	126.6M	157.1M	185.5M	350M	439.3M	461.3M
Common Stock Shares Outstanding	95.7M	97.8M	97.9M	98.9M	101M	61.8M
Liabilities And Stockholders Equity	1.3B	1.7B	2.1B	2.4B	3.3B	3.4B
Non Current Liabilities Total	103.8M	422M	452.7M	123.2M	364.6M	382.8M
Other Current Assets	160.5M	215.2M	261.5M	464.2M	97.8M	61.5M
Other Stockholder Equity	1.8B	1.8B	2.0B	2.1B	2.4B	2.5B
Total Liab	669.1M	608.5M	698.5M	660.9M	1.0B	1.1B
Property Plant And Equipment Gross	116.3M	127.4M	155.8M	145.6M	430.3M	451.8M
Total Current Assets	831M	1.0B	972.8M	1.5B	1.6B	1.7B
Accumulated Other Comprehensive Income	1.4M	1.8M	(1.7M)	(7.9M)	7M	7.4M
Short Term Debt	408.8M	10.3M	16.5M	169.4M	170.1M	178.6M
Short Term Investments	558.2M	613.9M	370.5M	726.4M	780.5M	819.5M
Other Liab	17.1M	9.7M	12.3M	29.7M	34.2M	24.8M
Other Assets	59.1M	674M	319.5M	330.9M	380.5M	399.6M
Long Term Debt	388.5M	408.8M	317.9M	335.1M	385.4M	404.6M
Common Stock Total Equity	89K	91K	92K	100K	115K	67.8K
Common Stock	89K	91K	92K	100K	115K	69.6K
Property Plant Equipment	33.9M	41.9M	44.6M	58.6M	52.7M	55.4M
Current Deferred Revenue	(46.2M)	(10.3M)	(16.5M)	339.9M	390.9M	410.4M
Net Tangible Assets	228.1M	1.1B	1.4B	1.7B	1.9B	2.0B
Retained Earnings Total Equity	(1.1B)	(725.4M)	(635.8M)	(406.8M)	(366.1M)	(384.4M)
Capital Surpluse	1.8B	1.8B	2.0B	2.1B	2.4B	1.6B
Inventory	17.3M	28M	30.5M	35.1M	38.3M	40.2M
Non Current Liabilities Other	103.8M	104.1M	117.6M	29.7M	10.3M	9.8M
Long Term Investments	299.7M	227.1M	560.7M	401.5M	849.4M	891.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
BAC	Bank of America
GM	General Motors

When determining whether Neurocrine Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurocrine Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurocrine Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurocrine Biosciences Stock:

How To Invest In Neurocrine

Details

Is Neurocrine Stock a good investment?

Details

What is Neurocrine Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Complementary Tools for Neurocrine Stock analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.

	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	CEOs Directory Screen CEOs from public companies around the world
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins

Is Neurocrine Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.648

Earnings Share

3.68

Revenue Per Share

20.147

Quarterly Revenue Growth

0.226

Return On Assets

0.1008

The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neurocrine Cash And Short Term Investments vs Other Current Assets Analysis

Cash And Short Term Investments vs Other Current Assets

Cash And Short Term Investments vs Other Current Assets Correlation Analysis

Correlation Coefficient

Cash And Short Term Investments

Other Current Assets

Neurocrine Biosciences fundamental ratios Correlations

Neurocrine Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Neurocrine Biosciences fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Neurocrine Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Stockholder Equity	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Net Receivables	+ 0.99	Total Stockholder Equity
Net Receivables	+ 0.99	Accounts Payable

Common Stock Shares Outstanding	- 0.45	Retained Earnings
Retained Earnings	- 0.45	Short Long Term Debt Total
Cash	- 0.37	Net Debt
Other Liab	- 0.27	Cash
Other Assets	- 0.18	Net Debt
Other Liab	- 0.17	Other Current Liab